| Literature DB >> 31690400 |
Abstract
Immunobiologic agents are an important therapeutic alternative for severe asthma, atopic dermatitis, and chronic urticaria. In this article, we reviewed the most relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-IL-5 (mepolizumab, reslizumab, and benralizumab), and anti-IL-4/IL-13 (dupilumab) treatments for these allergic diseases. In addition, we discussed emerging immunobiologic therapies, such as tezepelumab.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31690400 DOI: 10.2500/aap.2019.40.4277
Source DB: PubMed Journal: Allergy Asthma Proc ISSN: 1088-5412 Impact factor: 2.587